Skip to main content
. 2014 Jan 27;7(4):897–900. doi: 10.3892/etm.2014.1505

Table I.

Local therapeutic efficacy comparison of the HCC group (n=34) and the MLC group (n=22) following RFA.

Group Complete ablation rate (%) Recurrence rate (%) Distant recurrence rate (%)
HCC 32/34 (94.1) 5/34 (14.7) 4/34 (11.8)
MLC 21/22 (95.4) 2/22 (9.1) 8/22 (36.4)
P-value 1.000 0.836 0.063

HCC, hepatocellular carcinoma; MLC, metastatic liver cancer; RFA, radiofrequency ablation.